DMS contracts with hospitals and health care systems to provide mobile imaging services on site – we do not provide home-based imaging services.
Gadolinium-based contrast agents (GBCAs) are the only approved class of drugs for use with MRI in the United States. There has been increasing concern among radiologists about potential legal exposure from its use. Several patients have come forward reporting adverse...
Over the past few years, the imaging community has had a whirlwind of technological advances and the introduction of a handful of new imaging agents, especially in the PET/CT space. In this article, we will explore one of the more impactful PET/CT imaging agent that...
When hospitals and imaging facilities purchase new equipment, such as an MRI, CT, or PET/CT camera, there is often a period of down-time during construction or installation. In most instances, the hospital is responsible for finding an interim imaging provider to...
WEST FARGO, North Dakota – DMS Health Technologies (DMS), one of the nation’s largest mobile imaging providers, announced that it has finalized terms to acquire the assets of Advanced Imaging Management (AIM), a national provider of mobile MRI and ultrasound systems...
As patients who put off medical services surge back into the healthcare system, radiology and imaging departments are feeling the impact. Imaging departments who experienced historically low volumes in the Spring are now faced with backlogs that stretch weeks. The...
Imaging studies always require a good balance between patient comfort and efficacy of the imaging work. For many years, the only option on the MRI market was a closed bore machine, essentially a tube that patients lie inside. The main problem with these is...
Precision radiopharmaceutical diagnostic imaging procedures help identify abnormalities early in the progress of a disease —before many medical problems are apparent with other diagnostic tests. Despite the proven effectiveness of radiopharmaceuticals, such as Axumin...
Recently, the FDA provided approval for the use of two new PET radiopharmaceuticals, Cerianna and Tauvid. Cerianna is a molecular imaging agent indicated for use in PET imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients...
Gadolinium-based contrast agents (GBCAs) are the only approved class of drugs for use with MRI in the United States. There has been increasing concern among radiologists about potential legal exposure from its use. Several patients have come forward reporting adverse...
Over the past few years, the imaging community has had a whirlwind of technological advances and the introduction of a handful of new imaging agents, especially in the PET/CT space. In this article, we will explore one of the more impactful PET/CT imaging agent that...
When hospitals and imaging facilities purchase new equipment, such as an MRI, CT, or PET/CT camera, there is often a period of down-time during construction or installation. In most instances, the hospital is responsible for finding an interim imaging provider to...
WEST FARGO, North Dakota – DMS Health Technologies (DMS), one of the nation’s largest mobile imaging providers, announced that it has finalized terms to acquire the assets of Advanced Imaging Management (AIM), a national provider of mobile MRI and ultrasound systems...
As patients who put off medical services surge back into the healthcare system, radiology and imaging departments are feeling the impact. Imaging departments who experienced historically low volumes in the Spring are now faced with backlogs that stretch weeks. The...
Imaging studies always require a good balance between patient comfort and efficacy of the imaging work. For many years, the only option on the MRI market was a closed bore machine, essentially a tube that patients lie inside. The main problem with these is...
Precision radiopharmaceutical diagnostic imaging procedures help identify abnormalities early in the progress of a disease —before many medical problems are apparent with other diagnostic tests. Despite the proven effectiveness of radiopharmaceuticals, such as Axumin...
Recently, the FDA provided approval for the use of two new PET radiopharmaceuticals, Cerianna and Tauvid. Cerianna is a molecular imaging agent indicated for use in PET imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients...